Loading
A phase 2 trial of Medium dose for 15-HPV vaccine in advanced solid tumours, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.
To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years is a phase 2 interventional study registered as NCT06756269 by Shanghai Bovax Biotechnology Co., Ltd., with 330 participants planned, started 2025-01-15 and due to reach its primary completion in 2025-10-30. Interventions recorded: Medium dose for 15-HPV vaccine, High dose for 15-HPV vaccine, Placebo and 9-HPV vaccine.
Shares Shanghai Bovax Biotechnology and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.